Back to Newsroom
Back to Newsroom

Himax Technologies Misses on Earnings by $0.01; Echo Therapeutics Misses on Q1 Revenues

Monday, 12 May 2014 12:10 AM

Topic:

AstraZeneca PLC (NYSE: AZN) - For an in-depth report on AstraZeneca PLC follow: www.BullTrends.com/stockquote/AZN

Shares of AstraZeneca closed down nearly 2% on Friday with about 15 million shares traded. The stock was one of the biggest decliners on the NYSE. Pfizer, the world’s largest pharmaceutical company is attempting to acquire AstraZeneca with opposition from federal lawmakers about Pfizer consolidating headquarters in the U.K.

eBay Inc. (NASDAQ: EBAY) - For an in-depth report on eBay Inc. follow: www.BullTrends.com/stockquote/EBAY

eBay shares closed modestly in the green this past Friday on about 14.2 million shares traded. The stock was one of the most active stocks on the NASDAQ. The former head of a company that was bought by eBay, Christopher Saridakis, pleaded guilty to securities fraud after prosecutors said he tipped friends to the pending 2011 acquisition of the e-commerce business he headed.

Himax Technologies, Inc. (NASDAQ: HIMX) - For an in-depth report on Himax Technologies, Inc. follow: www.BullTrends.com/stockquote/HIMX

Shares of Himax Technologies closed down 13.25% on about 15.7 million shares traded. The stock was one of the biggest decliners on the NASDAQ this past Friday. The company missed estimates for earnings in the first quarter and gave guiding below estimates for the second quarter. For Q1 Himax reported earnings of 9 cents when the Capital IQ Consensus Estimate was 10 cents. Revenue for the quarter was $194.6 million while analysts expected revenue of $194.2 million.

Echo Therapeutics, Inc. (NASDAQ: ECTE) - For an in-depth report on Echo Therapeutics, Inc. follow:  www.BullTrends.com/stockquote/ECTE

Shares of ECTE closed down 29.64% on about 1 million shares traded. The stock was one of the biggest decliners on the NASDAQ and hit a new yearly low of $2.01 during intra-day trading. The company reported Q1 revenue of $19,107 when the consensus was $20,000.

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

Topic:
Back to newsroom
Back to Newsroom
Share by: